October 31, 2025 — Leads & Copy —
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The termination of the waiting period under the HSR Act satisfies the regulatory review requirements under the previously announced proposed acquisition of Metsera, which was set to expire on November 7.
At Pfizer, science and global resources are applied to deliver therapies that extend and improve lives. Pfizer strives to set standards for quality, safety, and value in healthcare product discovery, development, and manufacture. Pfizer colleagues advance wellness, prevention, treatments, and cures for diseases. Pfizer collaborates with healthcare providers, governments, and communities to support access to healthcare worldwide. For over 150 years, Pfizer has worked to make a difference.
For more information, visit www.Pfizer.com and follow Pfizer on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube, and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251031089764/en/
Source: Pfizer
